Peer-reviewed veterinary case report
Molecular iodine with doxorubicin reduces side effects in dog mammary
By Zambrano-Estrada, Xóchitl et al.·Published in BMC veterinary research·2018·Instituto de Neurobiologí·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.
- Species:
- dog
Plain-English summary
A group of 27 dogs with mammary cancer received a new treatment combining molecular iodine and a chemotherapy drug called doxorubicin. The dogs were split into two groups: one received the standard treatment every 21 days, while the other had more frequent doses every 15 days. The results showed that the more frequent treatment with iodine helped reduce side effects and improve the overall response to the cancer treatment. After ten months, about 67-73% of the dogs that received iodine before and after surgery were disease-free, suggesting this combination could be a promising option for treating canine mammary cancer.
People also search for: dog mammary cancer treatment · doxorubicin side effects in dogs · iodine for dog cancer
Abstract
BACKGROUND: Mammary cancer has a high incidence in canines and is an excellent model of spontaneous carcinogenesis. Molecular iodine (I) exerts antineoplastic effects on different cancer cells activating re-differentiation pathways. In co-administration with anthracyclines, Iimpairs chemoresistance installation and prevents the severity of side effects generated by these antineoplastic drugs. This study is a random and double-blind protocol that analyzes the impact of I(10 mg/day) in two administration schemes of Doxorubicin (DOX; 30 mg/m2) in 27 canine patients with cancer of the mammary gland. The standard scheme (sDOX) includes four cycles of DOX administered intravenously for 20 min every 21 days, while the modified scheme (mDOX) consists of more frequent chemotherapy (four cycles every 15 days) with slow infusion (60 min). In both schemes, Ior placebo (colored water) was supplemented daily throughout the treatment. RESULTS: mDOX attenuated the severity of adverse events (VCOG-CTCAE) in comparison with the sDOX group. The overall tumor response rate (RECIST criteria) for all dogs was 18% (interval of reduction 48-125%), and no significant difference was found between groups. Isupplementation enhances the antineoplastic effect in mDOX, exhibiting a significant decrease in the tumor epithelial fraction, diminished expression of chemoresistance (MDR1 and Survivin) and invasion (uPA) markers and enhanced expression of the differentiation factor known as peroxisome proliferator-activated receptors type gamma (PPARγ). Significant tumor lymphocytic infiltration was also observed in both I-supplemented groups. The ten-month survival analysis showed that the entire Isupplementation (before and after surgery) induced 67-73% of disease-free survival, whereas supplementation in the last period (only after surgery) produced 50% in both schemes. CONCLUSIONS: The mDOX+Ischeme improves the therapeutic outcome, diminishes the invasive capacity, attenuates the adverse events and increases disease-free survival. These data led us to propose mDOX+Ias an effective treatment for canine mammary cancer.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29530037/